Compare PCRX & LEGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | LEGH |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 691.6M |
| IPO Year | 2010 | 2018 |
| Metric | PCRX | LEGH |
|---|---|---|
| Price | $25.34 | $28.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $30.25 | $25.00 |
| AVG Volume (30 Days) | ★ 436.7K | 62.6K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | 0.19 | ★ 1.44 |
| Revenue | ★ $541,533,000.00 | $164,567,000.00 |
| Revenue This Year | $6.78 | $11.90 |
| Revenue Next Year | $8.54 | $6.58 |
| P/E Ratio | $133.63 | ★ $20.22 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $18.29 |
| 52 Week High | $27.66 | $31.34 |
| Indicator | PCRX | LEGH |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 59.22 |
| Support Level | $22.13 | $28.00 |
| Resistance Level | $27.03 | $30.92 |
| Average True Range (ATR) | 0.84 | 0.90 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 72.07 | 76.11 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The Company manufactures and provides for the transport of manufactured homes, provides wholesale financing to dealers and mobile home parks, provides retail financing to consumers, and is involved in financing and developing new manufactured home communities. The Company manufactures its mobile homes at plants in Fort Worth, Texas; Commerce, Texas; and Eatonton, Georgia. The Company also sells homes directly to consumers, through its own retail stores, and to dealers and mobile home parks.